Dr. Tanios Bekaii-Saab

Research on adagrasib has demonstrated promising clinical activity in patients with gastrointestinal cancers that harbor KRAS G12C mutations.

As coronavirus disease 2019 (COVID-19) challenges health care systems across the United States, it poses an extra challenge for physicians in the field of oncology. "Patients ...